Goldilocks – Our MNPs are just the right fit for kidney disease

Goldilocks Therapeutics was formed to develop preventatives and/or treatments for acute kidney injury (AKI), polycystic kidney disease (PKD), and other under-treated kidney conditions by leveraging the Company’s proprietary mesoscale nanoparticles (MNPs) to specifically target therapeutic payloads to the renal tubule epithelium.  This approach – and the associated sustained release of therapeutic compounds – holds the potential to vastly increase the local concentration of drug at the renal tubules, thereby providing improved efficacy with little or no systemic side effects.